ClinicalTrials.gov ID NCT04647526Sponsor POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyLocal PI Di Maria JiangConditions The primary objective of the study is to determine the efficacy of -PNT2002 (-PSMA-I&T) versus abiraterone or enzalutamide in delaying radiographic progression…
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
ClinicalTrials.gov ID NCT02743741Sponsor University Health Network, TorontoLocal PI Rebecca Wong Conditions: This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by…
A Phase II Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Prostate specific membrane antigen (PSMA)-avid Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
ClinicalTrials.gov ID NCT03939689Sponsor Progenics Pharmaceuticals, Inc.Local PI Neil Fleshner Conditions: This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared to enzalutamide alone in participants with…
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
ClinicalTrials.gov ID NCT04663997Sponsor Canadian Cancer Trials GroupLocal PI Aaron Hansen & Di Maria Jiang Conditions: The standard or usual treatment for this disease is a chemotherapy drug called docetaxel, given by intravenous every 3 weeks, for up to 12 treatments.…
A Phase 1/ 2 Study of (225Ac)-FPI-1434 Injection
ClinicalTrials.gov ID NCT03746431Sponsor Fusion Pharmaceuticals Inc.Local PI Ale Berlin Conditions: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of -FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours…